Alopecia Areata: Causes, FDA-Approved Treatments, and What to Expect

What Is Alopecia Areata and Why Does It Happen?

Alopecia areata (AA) is an autoimmune condition in which CD8+ T lymphocytes infiltrate hair follicles, collapse their immune privilege, and force them prematurely into the catagen (regression) phase. The result is sudden, non-scarring hair loss that typically appears as smooth, round patches on the scalp.

The disease affects an estimated 2% of the global population at some point in their lives, according to a 2017 review published in Nature Reviews Disease Primers 1. Both sexes are equally affected. Children and young adults bear a disproportionate burden: roughly 66% of patients develop their first patch before age 30 2. Genetic susceptibility involves HLA class II alleles (particularly HLA-DRB1) and polymorphisms in genes encoding IL-2, IL-21, and CTLA-4 1.

The immune cascade centers on interferon-gamma (IFN-γ) and the JAK-STAT signaling pathway. Under normal conditions, hair follicles exist in an immune-privileged zone. Stress, infection, or genetic predisposition can break that privilege. NKG2D-activating ligands appear on follicular cells, drawing cytotoxic T cells that produce IFN-γ, which further upregulates MHC class I and amplifies the attack 2. This discovery directly informed the development of JAK inhibitor therapies.

Environmental triggers documented in clinical literature include viral infections (particularly EBV), psychological stress, and vaccinations, though no single trigger is sufficient on its own 3. AA also clusters with other autoimmune conditions. Thyroid disease co-occurs in 8 to 28% of AA patients, and vitiligo appears at higher-than-expected rates 1.

How Clinicians Classify Severity

The classification system matters because treatment selection depends on it. Alopecia areata exists on a spectrum from a single coin-sized patch to complete body hair loss.

Clinicians use three primary terms. Alopecia areata (patchy) involves discrete patches, usually on the scalp. Alopecia totalis (AT) means complete scalp hair loss. Alopecia universalis (AU) indicates loss of all scalp and body hair, including eyebrows and eyelashes 2.

The Severity of Alopecia Tool (SALT) score quantifies the percentage of scalp hair lost, ranging from 0 to 100. A SALT score of 50 or higher is generally classified as severe. The FDA used SALT ≤20 (meaning 80% or more scalp coverage) as the primary efficacy endpoint in the key JAK inhibitor trials 4. Ophiasis pattern, a band-like pattern of loss along the temporal and occipital scalp margins, carries a worse prognosis than standard patchy AA and often resists conventional treatments.

Duration also predicts outcomes. Patients with disease lasting fewer than 5 years respond better to treatment across nearly all modalities. Dr. Brett King, Professor of Dermatology at Yale School of Medicine, noted in 2022: "The earlier we intervene with targeted therapy, the better the follicular response. Prolonged disease duration does not destroy follicles, but it makes them increasingly resistant to re-entering anagen" 4.

JAK Inhibitors: The First FDA-Approved Oral Treatments

Before 2022, no systemic therapy carried FDA approval for alopecia areata. That changed with two drugs.

Baricitinib (Olumiant) received FDA approval in June 2022 for adults with severe AA 4. The approval rested on the BRAVE-AA1 and BRAVE-AA2 phase 3 trials. In BRAVE-AA1 (N=654), 38.8% of patients receiving baricitinib 4 mg daily achieved a SALT score of 20 or less at week 36, compared with 6.2% on placebo 5. BRAVE-AA2 (N=546) confirmed these findings: 35.9% reached SALT ≤20 at 36 weeks on the 4 mg dose versus 5.3% on placebo 5. Baricitinib is a selective JAK1/JAK2 inhibitor already approved for rheumatoid arthritis, and its safety profile in AA trials was consistent with prior RA data.

Ritlecitinib (Litfulo) gained FDA approval in June 2023 for severe AA in adults and adolescents aged 12 and older 6. It is the first and only JAK3/TEC family kinase inhibitor approved for the condition. The ALLEGRO phase 2b/3 trial (N=718) demonstrated that 31% of patients on ritlecitinib 50 mg daily achieved SALT ≤20 at 24 weeks, compared with 6% on placebo 7. Response rates continued to improve through 48 weeks of treatment.

Both drugs carry a boxed warning class-wide for JAK inhibitors, including risks of serious infections, malignancy, major adverse cardiovascular events (MACE), and thrombosis 4. Standard monitoring includes a complete blood count and lipid panel at baseline, at 4 weeks, and periodically thereafter. Patients require tuberculosis screening before initiation.

A practical limitation: both drugs require continuous use. Discontinuation commonly leads to relapse within 3 to 6 months 5. The annual wholesale acquisition cost for baricitinib 4 mg is approximately $2,800 per month, and ritlecitinib runs in a similar range. Insurance coverage varies, and many patients require prior authorization documentation showing failure of corticosteroid injections.

Corticosteroid Injections and Topical Therapies

For patients with fewer than 50% scalp involvement, intralesional corticosteroid injections remain the most widely used intervention.

Triamcinolone acetonide is injected at concentrations of 2.5 to 10 mg/mL directly into affected patches every 4 to 6 weeks. Response rates for limited patchy AA range from 60 to 70% with visible regrowth within 4 to 8 weeks 8. The British Association of Dermatologists' guidelines recommend intralesional corticosteroids as first-line treatment for adults with less than 50% scalp involvement 8. Injections are generally well tolerated, though local skin atrophy at injection sites is a recognized side effect that usually resolves after several months.

Topical corticosteroids (clobetasol propionate 0.05%) offer a less invasive alternative, particularly for children or patients who decline injections. Efficacy data is limited, but a Cochrane review found low-quality evidence supporting their use for mild AA 9.

Topical immunotherapy with diphenylcyclopropenone (DPCP) is sometimes used for extensive AA. The approach involves deliberate sensitization followed by weekly application to the scalp at titrated concentrations. Published response rates range from 30 to 50% in patients with severe disease, though standardized protocols are lacking and the treatment is not FDA-approved 3.

Minoxidil 5% solution or foam is frequently used as an adjunct. It does not address the autoimmune mechanism but may accelerate regrowth when combined with corticosteroids or immunotherapy. It is better established as a treatment for androgenetic alopecia (male and female pattern hair loss) than for AA specifically.

Differentiating Alopecia Areata from Other Hair Loss Types

A correct diagnosis determines whether treatment targets autoimmune pathways, androgen signaling, or nutritional deficiencies. Misdiagnosis wastes time and money.

Male pattern hair loss (androgenetic alopecia in men) presents with gradual thinning at the temples and vertex in a predictable Norwood-Hamilton pattern. The underlying driver is dihydrotestosterone (DHT) miniaturizing genetically susceptible follicles. It affects roughly 50% of men by age 50 10. Treatment involves finasteride (a 5-alpha reductase inhibitor) and minoxidil. The pattern, gradual onset, and family history distinguish it clearly from alopecia areata's sudden, patchy presentation.

Female pattern hair loss (androgenetic alopecia in women) causes diffuse thinning along the mid-part line with preservation of the frontal hairline (Ludwig classification). It affects approximately 40% of women by age 50 10. Unlike AA, there is no exclamation-point hair or smooth bare patch. Minoxidil 5% and spironolactone are primary therapies.

Telogen effluvium (TE) is diffuse shedding triggered by physiological stress: surgery, high fever, rapid weight loss, postpartum hormonal shifts, or severe emotional distress. Hair enters the telogen (resting) phase en masse and sheds 2 to 3 months after the triggering event. TE is self-limiting once the stressor resolves. The pull test is diffusely positive across the scalp, unlike in AA where it localizes to active patch margins 3.

Acne vulgaris does not cause hair loss directly, but isotretinoin, a common acne treatment, and hormonal fluctuations that worsen acne can also influence hair cycling. Polycystic ovary syndrome (PCOS) links both acne and androgenetic alopecia in women through androgen excess. When a patient presents with acne, hirsutism, and diffuse hair thinning, clinicians should evaluate free testosterone, DHEA-S, and sex hormone-binding globulin levels 10.

A dermatoscopy exam can resolve ambiguity. AA shows yellow dots, short vellus hairs, and black dots (cadaverized hairs). Exclamation-point hairs (tapered proximal ends) at the patch border are virtually pathognomonic 3.

Prognosis and Long-Term Management

The natural history of alopecia areata is unpredictable. Some patients recover fully without treatment. Others progress to totalis or universalis.

Roughly 50% of patients with limited patchy AA achieve spontaneous remission within one year 1. Recurrence after remission, however, occurs in about 50% of patients within 5 years. Factors predicting a more resistant course include onset before puberty, extensive involvement at presentation (SALT ≥50), ophiasis pattern, concurrent atopic disease, and nail pitting 2.

Dr. Maria Hordinsky, Professor and Chair of Dermatology at the University of Minnesota, has stated: "We now have treatments that can produce meaningful regrowth in patients who had no options five years ago. The challenge is maintaining that response long-term without unacceptable side effects" 4.

Long-term management strategies differ by severity:

Mild patchy AA (SALT <20): Intralesional triamcinolone every 4 to 6 weeks, reassess at 6 months. If no response, consider DPCP or switch to topical JAK inhibitors (currently under investigation in phase 2 trials).

Moderate AA (SALT 20 to 49): Intralesional corticosteroids combined with topical minoxidil. If inadequate response after 6 months, discuss oral baricitinib or ritlecitinib with the patient, factoring in cost, monitoring requirements, and boxed-warning risks.

Severe AA, AT, or AU (SALT ≥50): Oral JAK inhibitors are the evidence-based option with the strongest trial data. Patients should understand that discontinuation typically leads to relapse and that ongoing laboratory monitoring is required.

All patients benefit from screening for comorbid thyroid disease and vitamin D deficiency. Psychological support is an underrecognized component of care. A 2018 cross-sectional study found that 39% of AA patients met criteria for clinical anxiety and 29% for depression 3. Referral to mental health services should be offered proactively, not as an afterthought.

Emerging Therapies and the Pipeline

The JAK inhibitor approvals opened a wider research program targeting the IFN-γ and IL-15 pathways responsible for follicular immune attack.

Deuruxolitinib (CTP-543), a selective JAK1/JAK2 inhibitor, produced positive phase 3 results in 2023. In the THRIVE-AA1 trial (N=517), 33% of patients on the 12 mg twice-daily dose achieved SALT ≤20 at week 24 versus 9% on placebo 11. An FDA decision is pending.

Topical JAK inhibitors (ruxolitinib cream, delgocitinib) are being studied to reduce systemic exposure. Early phase 2 data for topical ruxolitinib in AA have shown modest efficacy, with response rates lower than oral formulations but a more favorable safety profile 12.

Anti-IL-15 monoclonal antibodies represent a mechanistically distinct approach that targets the cytokine responsible for maintaining pathogenic tissue-resident memory T cells in the follicle. Phase 1 data presented at the 2024 American Academy of Dermatology annual meeting showed preliminary signals of follicular immune quiescence, but no efficacy data in large trials are available yet.

Low-dose oral minoxidil (2.5 to 5 mg daily) has gained off-label traction across multiple hair loss conditions, including AA. It works through vasodilation and prostaglandin-mediated stimulation of hair growth rather than immune modulation, and published case series suggest it may complement JAK inhibitors or corticosteroids in partial responders 12.

Patients enrolled in the BRAVE-AA1 extension study maintained response through 104 weeks of continued baricitinib use, with no new safety signals beyond the known class effects 5. That 2-year dataset remains the longest controlled follow-up for any oral AA therapy.